High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?

被引:23
作者
Mohty, Mohamad [1 ,2 ,3 ]
Malard, Florent [1 ,2 ,3 ]
Savani, Bipin N. [4 ,5 ]
机构
[1] Hop St Antoine, Dept Hematol, F-75571 Paris 12, France
[2] INSERM, UMR 938, Paris, France
[3] Univ Paris 06, Paris, France
[4] Vanderbilt Univ, Hematol & Stem Cell Transplantat Sect, Dept Med, Div Hematol Oncol,Med Ctr, Nashville, TN 37235 USA
[5] Vet Affairs Med Ctr, Nashville, TN 37212 USA
关键词
Allogeneic hematopoietic cell transplantation; Myeloablative conditioning regimen; High-dose total body irradiation; Long-term complication; Nonrelapse mortality; Overall survival; BONE-MARROW-TRANSPLANTATION; LONG-TERM SURVIVORS; CHRONIC KIDNEY-DISEASE; ACUTE MYELOID-LEUKEMIA; COMORBIDITY INDEX; EUROPEAN GROUP; WORKING PARTY; SOLID CANCERS; 1ST REMISSION; CYCLOPHOSPHAMIDE;
D O I
10.1016/j.bbmt.2014.09.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the last decade, the care of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) has significantly improved, leading to a decrease in deaths related to allo-HCT as well as improved long-term survival. However, for many patients, long-term survivorship is associated with a substantial burden of chronic morbidities. Indeed, malignant and nonmalignant late complications after allo-HCT are numerous and usually multifactorial, with all organs and tissues a potential target. In many cases, these long-term side effects are associated with the use of high-dose total body irradiation, myeloablative conditioning regimens, and the onset of chronic graft-versus-host disease. It appears to be essential to change the natural history of these late effects. This requires the introduction of improved conditioning regimens and the development of lifelong monitoring controls, patient counseling, and preventative treatment measures. This approach will allow us to pursue our efforts to improve patient outcome. (C) 2015 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:620 / 624
页数:5
相关论文
共 34 条
[1]   Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation [J].
Al-Hazzouri, Ahmed ;
Cao, Qing ;
Burns, Linda J. ;
Weisdorf, Daniel J. ;
Majhail, Navneet S. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (06) :658-663
[2]   Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study [J].
Baker, K. Scott ;
Ness, Kirsten K. ;
Steinberger, Julia ;
Carter, Andrea ;
Francisco, Liton ;
Burns, Linda J. ;
Sklar, Charles ;
Forman, Stephen ;
Weisdorf, Daniel ;
Gurney, James G. ;
Bhatia, Smita .
BLOOD, 2007, 109 (04) :1765-1772
[3]   Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: A study of the European Group for Blood and Marrow Transplantation [J].
Belkacemi, Y ;
Labopin, M ;
Vernant, JP ;
Prentice, HG ;
Tichelli, A ;
Schattenberg, A ;
Boogaerts, MA ;
Ernst, P ;
Della Volpe, A ;
Goldstone, AH ;
Jouet, JP ;
Verdonck, LF ;
Locasciulli, A ;
Rio, B ;
Ozsahin, M ;
Gorin, NC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (03) :659-668
[4]   Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study [J].
Bhatia, Smita ;
Francisco, Liton ;
Carter, Andrea ;
Sun, Can-Lan ;
Baker, K. Scoff ;
Gurney, James G. ;
McGlave, Philip B. ;
Nademanee, Auayporn ;
O'Donnell, Margaret ;
Ramsay, Norma K. C. ;
Robison, Leslie L. ;
Snyder, David ;
Stein, Anthony ;
Forman, Stephen J. ;
Weisdorf, Daniel J. .
BLOOD, 2007, 110 (10) :3784-3792
[5]  
Cheuk Daniel Kl, 2013, World J Transplant, V3, P99, DOI 10.5500/wjt.v3.i4.99
[6]   Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation [J].
Choi, Michael ;
Sun, Can-Lan ;
Kurian, Seira ;
Carter, Andrea ;
Francisco, Liton ;
Forman, Stephen J. ;
Bhatia, Smita .
CANCER, 2008, 113 (07) :1580-1587
[7]   Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI [J].
Copelan, Edward A. ;
Hamilton, Betty K. ;
Avalos, Belinda ;
Ahn, Kwang Woo ;
Bolwell, Brian J. ;
Zhu, Xiaochun ;
Aljurf, Mahmoud ;
van Besien, Koen ;
Bredeson, Christopher ;
Cahn, Jean-Yves ;
Costa, Luciano J. ;
de Lima, Marcos ;
Gale, Robert Peter ;
Hale, Gregory A. ;
Halter, Joerg ;
Hamadani, Mehdi ;
Inamoto, Yoshihiro ;
Kamble, Rammurti T. ;
Litzow, Mark R. ;
Loren, Alison W. ;
Marks, David I. ;
Olavarria, Eduardo ;
Roy, Vivek ;
Sabloff, Mitchell ;
Savani, Bipin N. ;
Seftel, Matthew ;
Schouten, Harry C. ;
Ustun, Celalettin ;
Waller, Edmund K. ;
Weisdorf, Daniel J. ;
Wirk, Baldeep ;
Horowitz, Mary M. ;
Arora, Mukta ;
Szer, Jeff ;
Cortes, Jorge ;
Kalaycio, Matt E. ;
Maziarz, Richard T. ;
Saber, Wael .
BLOOD, 2013, 122 (24) :3863-3870
[8]  
Duong HK, 2014, BIOL BLOOD MARROW TR
[9]   Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party [J].
Friedman, Debra L. ;
Rovo, Alicia ;
Leisenring, Wendy ;
Locasciulli, Anna ;
Flowers, Mary E. D. ;
Tichelli, Andre ;
Sanders, Jean E. ;
Deeg, H. Joachim ;
Socie, Gerard .
BLOOD, 2008, 111 (02) :939-944
[10]   Renal function after autologous bone marrow transplantation in children:: a long-term prospective study [J].
Frisk, P ;
Bratteby, LE ;
Carlson, K ;
Lönnerholm, G .
BONE MARROW TRANSPLANTATION, 2002, 29 (02) :129-136